Rgenta Therapeutics has received FDA approval for its new drug, RGT-61159, to treat various cancers by targeting RNA splicing to inhibit MYB protein production.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing
Rgenta Therapeutics' RGT-61159 gains IND approval to treat cancers
